A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

dc.contributor.authorVan Vollenhoven, Ronald F.
dc.contributor.authorVoskuyl, Alexandre E.
dc.contributor.authorBertsias, George
dc.contributor.authorAranow, Cynthia
dc.contributor.authorAringer, Martin
dc.contributor.authorArnaud, Laurent
dc.contributor.authorAskanase, Anca
dc.contributor.authorBalá ová, Petra
dc.contributor.authorBonfa, Eloisa
dc.contributor.authorBootsma, Hendrika
dc.contributor.authorBoumpas, Dimitrios
dc.contributor.authorBruce, Ian N.
dc.contributor.authorCervera i Segura, Ricard, 1960-
dc.contributor.authorClarke, Ann E.
dc.contributor.authorConey, Cindy
dc.contributor.authorCostedoat-Chalumeau, Nathalie
dc.contributor.authorCzirják, László
dc.contributor.authorDerksen, R. H. W. M.
dc.contributor.authorDoria, Andrea
dc.contributor.authorDörner, Thomas
dc.contributor.authorFischer-Betz, Rebecca
dc.contributor.authorFritsch-Stork, Ruth
dc.contributor.authorGordon, Caroline
dc.contributor.authorGraninger, Winfried
dc.contributor.authorGyöri, Noémi
dc.contributor.authorHoussiau, Frédéric A.
dc.contributor.authorIsenberg, David
dc.contributor.authorJacobsen, Søren
dc.contributor.authorJayne, David
dc.contributor.authorKuhn, Annegret
dc.contributor.authorLe Guern, Véronique
dc.contributor.authorLerstrøm, Kirsten
dc.contributor.authorLevy, Roger A.
dc.contributor.authorMachado-Ribeiro, Francinne
dc.contributor.authorMariette, Xavier
dc.contributor.authorMissaykeh, Jamil
dc.contributor.authorMorand, Eric
dc.contributor.authorMosca, Marta
dc.contributor.authorInanc, Murat
dc.contributor.authorNavarra, Sandra
dc.date.accessioned2018-06-22T08:07:58Z
dc.date.available2018-06-22T08:07:58Z
dc.date.issued2016-11-24
dc.date.updated2018-06-22T08:07:58Z
dc.description.abstractObjectives Treat-to-target recommendations have identified 'remission' as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE. Methods An international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%. Results The task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions: 1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by . (reference to symptoms, signs, routine labs). 2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment. 3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics. The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life. Conclusions The work of this international task force provides a framework for testing different definitions of remission against long-term outcomes.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec678610
dc.identifier.issn0003-4967
dc.identifier.pmid27884822
dc.identifier.urihttps://hdl.handle.net/2445/123199
dc.language.isoeng
dc.publisherBMJ Publishing Group
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1136/annrheumdis-2016-209519
dc.relation.ispartofAnnals of the Rheumatic Diseases, 2016, vol. 76, num. 3, p. 554-561
dc.relation.urihttps://doi.org/10.1136/annrheumdis-2016-209519
dc.rights(c) BMJ Publishing Group, 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationLupus eritematós
dc.subject.classificationMalalties autoimmunitàries
dc.subject.classificationFarmacologia
dc.subject.classificationEstudi de casos
dc.subject.otherLupus erythematosus
dc.subject.otherAutoimmune diseases
dc.subject.otherPharmacology
dc.subject.otherCase studies
dc.titleA framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
678610.pdf
Mida:
533.34 KB
Format:
Adobe Portable Document Format